Evidence map›Paper›PMID 27807182›Full record

ArticleNeurology2016

Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease.

Gennaro Pagano, Sophie Molloy, Peter G Bain, Eugenii A Rabiner, K Ray Chaudhuri, David J Brooks, Nicola Pavese

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. PET Imaging in Movement Disorders.Seminars in nuclear medicine · 2018
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.Journal of neural transmission (Vienna, Austria : 1996) · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gennaro PaganoFrom the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark.
Sophie MolloyFrom the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark.
Peter G BainFrom the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark.
Eugenii A RabinerFrom the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark.
K Ray ChaudhuriFrom the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark.
David J BrooksFrom the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark.
Nicola PaveseFrom the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark. nicola.pavese@imperial.ac.uk.

Funding

Medical Research Council G1100810Medical Research Council MC_U120036861
6 · The paper itself

Abstract

objectiveTo investigate the relationship between hypothalamic D3 dopamine receptor availability and severity of sleep problems in Parkinson disease (PD).

methodsTwelve patients were assessed with PET and the high-affinity dopamine D3 receptor radioligand [

resultsWe found that lower dopamine D3 receptor availability measured with [

conclusionIn our cohort of patients with PD, the occurrence of excessive daytime sleepiness was linked to reductions in hypothalamic dopamine D3 receptor availability. If these preliminary findings are confirmed in larger cohorts of patients with polysomnographic characterization, selective pharmacologic modulation of the dopaminergic D3 system could be used to increase daytime alertness in patients with PD.

Indexed as

BrainBrain MappingCohort StudiesDopamine AgentsFemaleHumansMaleMiddle AgedParkinson DiseasePositron-Emission TomographyRadiopharmaceuticalsReceptors, Dopamine D3Severity of Illness IndexSleep Wake DisordersSurveys and QuestionnairesDopamine AgentsDRD3 protein, humanRadiopharmaceuticalsReceptors, Dopamine D3

Identifiers

PMID27807182
PMCPMC5177673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.